APA (7th ed.) Citation

Bärtsch, M., Schlenzka, J., Mai, E. K., Merz, M., Hillengaß, J., Raab, M., . . . Goldschmidt, H. (2016). Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: A randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. BMC cancer, 16, . https://doi.org/10.1186/s12885-016-2321-2

Chicago Style (17th ed.) Citation

Bärtsch, Marc-Andrea, et al. "Rationale and Design of the German-Speaking Myeloma Multicenter Group (GMMG) Trial ReLApsE: A Randomized, Open, Multicenter Phase III Trial of Lenalidomide/dexamethasone Versus Lenalidomide/dexamethasone Plus Subsequent Autologous Stem Cell Transplantation and Lenalidomide Maintenance in Patients with Relapsed Multiple Myeloma." BMC Cancer 16 (2016). https://doi.org/10.1186/s12885-016-2321-2.

MLA (9th ed.) Citation

Bärtsch, Marc-Andrea, et al. "Rationale and Design of the German-Speaking Myeloma Multicenter Group (GMMG) Trial ReLApsE: A Randomized, Open, Multicenter Phase III Trial of Lenalidomide/dexamethasone Versus Lenalidomide/dexamethasone Plus Subsequent Autologous Stem Cell Transplantation and Lenalidomide Maintenance in Patients with Relapsed Multiple Myeloma." BMC Cancer, vol. 16, 2016, https://doi.org/10.1186/s12885-016-2321-2.